What is Zacks Research’s Forecast for Perrigo Q3 Earnings?

Perrigo Company plc (NYSE:PRGO) – Investment analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Perrigo in a research report issued on Wednesday, August 26th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.59 for the quarter, down from their previous forecast of $0.64. The consensus estimate for Perrigo’s current full-year earnings is $2.20 per share. Zacks Research also issued estimates for Perrigo’s Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.16 EPS, Q1 2027 earnings at $0.47 EPS, Q2 2027 earnings at $0.47 EPS, Q3 2027 earnings at $0.52 EPS, Q4 2027 earnings at $0.84 EPS, FY2027 earnings at $2.29 EPS, Q2 2028 earnings at $0.67 EPS and FY2028 earnings at $2.70 EPS.

Other analysts have also issued research reports about the company. Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo Price Performance

NYSE PRGO opened at $14.77 on Thursday. The stock has a 50-day simple moving average of $11.31 and a 200 day simple moving average of $11.42. Perrigo has a twelve month low of $9.23 and a twelve month high of $24.04. The stock has a market capitalization of $2.05 billion, a PE ratio of -1.18, a P/E/G ratio of 1.65 and a beta of 0.51. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.32 and a current ratio of 2.32.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Institutional Trading of Perrigo

Hedge funds have recently modified their holdings of the company. Geneos Wealth Management Inc. increased its position in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. Kestra Investment Management LLC boosted its stake in Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares in the last quarter. UMB Bank n.a. increased its holdings in Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after buying an additional 1,213 shares during the period. Finally, Meeder Asset Management Inc. bought a new stake in Perrigo in the 4th quarter valued at $28,000. Institutional investors own 95.91% of the company’s stock.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be paid a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 7.9%. The ex-dividend date is Friday, August 28th. Perrigo’s payout ratio is currently -9.27%.

Key Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Zacks raised Perrigo’s FY2026 EPS estimate to $2.16 from $2.10, bringing it closer to the broader consensus estimate of $2.20. The firm also increased its Q4 2027 forecast to $0.84 from $0.72, while projecting FY2027 and FY2028 EPS of $2.29 and $2.70, respectively.
• Neutral Sentiment: A Zacks value-investing comparison examined whether Perrigo or Neogen offers the better value opportunity. The article may support investor interest in PRGO, but it does not represent a new corporate development or a clear change in the company’s outlook. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Another Zacks article focused on whether value investors should buy Perrigo, highlighting the firm’s emphasis on earnings revisions, valuation, growth and momentum factors rather than announcing a new recommendation or company-specific catalyst. Should Value Investors Buy Perrigo Stock?
• Negative Sentiment: Zacks lowered several important forecasts: Q3 2026 EPS to $0.59 from $0.64, Q4 2026 to $0.64 from $0.72, Q1 2027 to $0.47 from $0.60, Q2 2027 to $0.47 from $0.58, Q3 2027 to $0.52 from $0.60, and FY2027 to $2.29 from $2.50. FY2028 was also trimmed slightly to $2.70 from $2.72.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.